blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3292121

EP3292121 - KINASE INHIBITORS AND THEIR USE IN CANCER THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.06.2021
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  03.07.2020
FormerGrant of patent is intended
Status updated on  27.02.2020
FormerExamination is in progress
Status updated on  14.02.2020
FormerGrant of patent is intended
Status updated on  06.10.2019
FormerExamination is in progress
Status updated on  25.01.2019
FormerRequest for examination was made
Status updated on  09.02.2018
FormerThe international publication has been made
Status updated on  11.11.2016
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Technische Universität Dortmund
August-Schmidt-Str. 4
44227 Dortmund / DE
[2018/11]
Inventor(s)01 / RAUH, Daniel
Baroper Kirchweg 34
44227 Dortmund / DE
02 / GONTLA, Rajesh
Hansmannstraße 17
44227 Dortmund / DE
03 / WEISNER, Jörn
An der Halde 3a
45699 Herten / DE
 [2018/11]
Representative(s)Michalski Hüttermann & Partner Patentanwälte mbB
Kaistraße 16A
40221 Düsseldorf / DE
[N/P]
Former [2018/11]Michalski Hüttermann & Partner Patentanwälte mbB
Speditionstraße 21
40221 Düsseldorf / DE
Application number, filing date16720132.603.05.2016
[2018/11]
WO2016EP59918
Priority number, dateEP2015016645805.05.2015         Original published format: EP 15166458
[2018/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016177746
Date:10.11.2016
Language:EN
[2016/45]
Type: A1 Application with search report 
No.:EP3292121
Date:14.03.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 10.11.2016 takes the place of the publication of the European patent application.
[2018/11]
Type: B1 Patent specification 
No.:EP3292121
Date:05.08.2020
Language:EN
[2020/32]
Search report(s)International search report - published on:EP10.11.2016
ClassificationIPC:C07D471/04
[2018/11]
CPC:
C07D471/04 (EP,US); A61P35/00 (EP,US); G01N33/57484 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/11]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:KINASEHEMMER UND DEREN VERWENDUNG IN DER KREBSTHERAPIE[2018/11]
English:KINASE INHIBITORS AND THEIR USE IN CANCER THERAPY[2018/11]
French:INHIBITEURS DE KINASE ET LEUR UTILISATION DANS LA THÉRAPIE DU CANCER[2019/42]
Former [2018/11]INHIBITEURS DE KINASE ET LEUR UTILISATION EN THÉRAPIE ANTICANCÉREUSE
Entry into regional phase01.12.2017National basic fee paid 
01.12.2017Designation fee(s) paid 
01.12.2017Examination fee paid 
Examination procedure01.12.2017Examination requested  [2018/11]
01.12.2017Date on which the examining division has become responsible
25.05.2018Amendment by applicant (claims and/or description)
29.01.2019Despatch of a communication from the examining division (Time limit: M04)
21.05.2019Reply to a communication from the examining division
07.10.2019Communication of intention to grant the patent
07.02.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
07.02.2020Fee for grant paid
07.02.2020Fee for publishing/printing paid
28.02.2020Communication of intention to grant the patent
25.06.2020Receipt of the translation of the claim(s)
Opposition(s)07.05.2021No opposition filed within time limit [2021/28]
Fees paidRenewal fee
29.05.2018Renewal fee patent year 03
29.05.2019Renewal fee patent year 04
18.03.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.05.2016
AL05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MK05.08.2020
MT05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
TR05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
LU03.05.2021
[2024/41]
Former [2024/29]HU03.05.2016
AL05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MK05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
TR05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
LU03.05.2021
Former [2024/22]HU03.05.2016
AL05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MK05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
LU03.05.2021
Former [2023/30]HU03.05.2016
AL05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
LU03.05.2021
Former [2023/27]HU03.05.2016
AL05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
LU03.05.2021
Former [2022/09]AL05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
LU03.05.2021
Former [2022/07]AL05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/36]AL05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/34]AL05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/28]AL05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/25]AL05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/22]CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/21]DK05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/10]ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/09]ES05.08.2020
FI05.08.2020
LT05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
PT07.12.2020
Former [2021/08]ES05.08.2020
FI05.08.2020
LT05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
PT07.12.2020
Former [2021/07]FI05.08.2020
LT05.08.2020
NO05.11.2020
Cited inInternational search[Y]WO2006065601  (MERCK & CO INC [US], et al) [Y] 1-15 * the whole document *;
 [Y]WO2006135627  (MERCK & CO INC [US], et al) [Y] 1-15* the whole document *;
 [Y]  - JASON G KETTLE ET AL, "Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 55, no. 3, doi:10.1021/JM201394E, ISSN 0022-2623, (20120209), pages 1261 - 1273, (20120116), XP002694653 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm201394e
by applicant   - Z. FANG; J. R. SIMARD; D. PLENKER; H. D. NGUYEN; T. PHAN; P. WOLLE; S. BAUMEISTER; D. RAUH, ACS CHEM. BIOL., (2015), vol. 10, pages 279 - 288
    - S. MARHADOUR; M.-A. BAZIN; P. MARCHAND, TETRAHEDRON LETT., (2012), vol. 53, pages 297 - 300
    - B. F. KRIPPENDORFF; R. NEUHAUS; P. LIENAU; A. REICHEL; W. HUISINGA, J. BIOMOL. SCREEN, (2009), vol. 14, pages 913 - 923
    - A. SHEVCHENKO; H. TOMAS; J. HAVLIS; J. V. OLSEN; M. MANN, NAT. PROTOC., (2006), vol. 1, pages 2856 - 2860
    - COX, M. MANN, NAT. BIOTECHNOL., (2008), vol. 26, pages 1367 - 1372
    - H. NAKATANI; M. KOBAYASHI; T. JIN; T. TAGUCHI; T. SUGIMOTO; T. NAKANO; S. HAMADA; K. ARAKI, CANCER SCI., (2005), vol. 96, pages 116 - 119
    - A. DUENSING; F. MEDEIROS; B. MCCONARTY; N. E. JOSEPH; D. PANIGRAHY; S. SINGER; C. D. FLETCHER; G. D. DEMETRI; J. A. FLETCHER, ONCOGENE, (2004), vol. 23, pages 3999 - 4006
    - B. P. RUBIN; S. SINGER; C. TSAO; A. DUENSING; M. L. LUX; R. RUIZ; M. K. HIBBARD; C. J. CHEN; S. XIAO; D. A. TUVESON, CANCER RES., (2001), vol. 61, pages 8118 - 8121
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.